Showing results 1 to 1 of 1
| Issue Date | Title | Journal Title |
|---|---|---|
| 2025 | Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 study | EUROPEAN JOURNAL OF CANCER |